Trials / Completed
CompletedNCT02596399
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers
A PHASE I, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY,TOLERABILITY, AND PHARMACOKINETICS OF DSTA4637S IN HEALTHY VOLUNTEERS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study in healthy volunteers, enrolled at a single site in the United States to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DSTA4637S | Participants will receive DSTA4637S intravenously on Day 1. |
| DRUG | Placebo | Participants will receive placebo matched to DSTA4637S intravenously on Day 1. |
Timeline
- Start date
- 2015-11-29
- Primary completion
- 2016-05-30
- Completion
- 2016-05-30
- First posted
- 2015-11-04
- Last updated
- 2018-03-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02596399. Inclusion in this directory is not an endorsement.